Model Informed Drug Development Archives

Video

Modeling Alzheimer’s Disease with Certara IQ™

Explore Certara IQ’s Alzheimer’s Disease model, enabling researchers to simulate neurodegenerative pathways, test therapies, and…

Certara2025 年 10 月 16 日

Video

Early Feasibility Assessment (EFA) with Certara IQ™

Learn how Certara IQ performs early feasibility assessments (EFA) to predict biotherapeutic dosing, guide candidate…

Certara2025 年 10 月 16 日

Video

Certara IQ™: Predicting Recommended Phase 2 Doses with Confidence

Learn how Certara IQ predicts recommended Phase 2 doses using advanced QSP modeling workflows that…

Certara2025 年 10 月 16 日

Video

Certara IQ™: Model-Informed First-In-Human (FIH) Dose Selection

Discover how Certara IQ uses QSP modeling to predict safe and effective First-In-Human doses, accelerating…

Certara2025 年 10 月 16 日

Video

Inside Certara IQ™: Building the Future of QSP with Josh Apgar & Chris Bouton

Hear from Certara experts on how Certara IQ modernizes QSP modeling with AI, collaboration tools,…

Certara2025 年 10 月 16 日

Publication

Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results

Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…

Certara2025 年 10 月 15 日

Conference

ICAComP 2025

Certara2025 年 10 月 8 日

Guide

MBMA vs. Meta-Analysis: Quick Comparison Guide

Discover how Model-Based Meta-Analysis (MBMA) outperforms traditional meta-analysis in drug development by predicting outcomes, informing…

Certara2025 年 10 月 8 日

Conference

Dutch Medicines Days

Certara2025 年 10 月 7 日

White Paper

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…

Certara2025 年 10 月 3 日

模型引导的药物开发

Modeling Alzheimer’s Disease with Certara IQ™

Early Feasibility Assessment (EFA) with Certara IQ™

Certara IQ™: Predicting Recommended Phase 2 Doses with Confidence

Certara IQ™: Model-Informed First-In-Human (FIH) Dose Selection

Inside Certara IQ™: Building the Future of QSP with Josh Apgar & Chris Bouton

Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results

ICAComP 2025

MBMA vs. Meta-Analysis: Quick Comparison Guide

Dutch Medicines Days

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

订阅时事通讯

快捷链接

解决方案

联系我们